The Fox Chase Cancer Center is under new leadership since the last review and continues as one of the nation's few free standing comprehensive cancer centers. The Center's mission is """"""""To prevail over cancer, marshaling excellence of heart and mind each day in the collaborative practice of bold scientific discovery, prevention strategies, and compassionate cancer care."""""""" Our vision is to be an acknowledged national leader in cancer research and medicine and a pre-eminent cancer center in the Philadelphia area. The new leadership in conjunction with advice from External Advisory Boards has consolidated the CCSG Research Programs from 11 to 5. These five Programs represent the core scientific strengths of the Fox Chase Cancer Center. At the last review 30 CCSG Shared Facilities and 2 support elements (Protocol Review and Monitoring System and Protocol Specific Research) were approved for funding with recommendations to consolidate facilities. This proposal requests partial support for 16 core facilities and 2 support elements. Developmental Funds are requested to strategically increase critical mass for these 5 research Programs over the CCSG funding cycle. A plan is presented to recruit 21 to 30 new and replacement investigators. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer-reviewed funding within 24 months of their appointment. Of that amount $5.1 million was garnered by investigators who were partially supported by Developmental Funds. Since the last submission, the Cancer Research Pavilion was completed as planned in 2010 and will provide much of the needed space for new investigator laboratories. The Leadership's vision includes a plan to increase team-based science via strategic keystone investments. These institutional investments are intended to expand the research portfolio of FCCC to include more """"""""team-based"""""""" grants such as Program Project Grants and SPOREs. Several team-based science grant proposals will be submitted over the next few years as a direct result of these keystone Investments. To meet the demand presented by a future increase in principal investigators, the Center plans to leverage $8 million of ARRA funds with $5.1 million of institutional investment to construct a Comparative Medical Facility (CMR). Since the last review, FCCC has implemented a formal review mechanism to evaluate and prioritize its CCSG Shared Research Resources. As a result, of this evaluation process, the number of Shared Research Resources has been streamlined.

Public Health Relevance

NCI-designated Cancer Centers such as Fox Chase Cancer Center serve as major source of discovery of the nature of cancer, and development of more effective approaches to prevention, diagnosis and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006927-50S8
Application #
8894665
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1997-07-21
Project End
2015-06-30
Budget Start
2014-09-01
Budget End
2015-06-30
Support Year
50
Fiscal Year
2014
Total Cost
Indirect Cost
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Nikonova, Anna S; Deneka, Alexander Y; Kiseleva, Anna A et al. (2018) Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 32:2735-2746
Singh, Tanu; Lee, Eric H; Hartman, Tiffiney R et al. (2018) Opposing Action of Hedgehog and Insulin Signaling Balances Proliferation and Autophagy to Determine Follicle Stem Cell Lifespan. Dev Cell 46:720-734.e6
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7

Showing the most recent 10 out of 1280 publications